All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Dexcom, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The second quarter 2020 non-GAAP amount excludes $7.8 million of incremental costs incurred as a result of the COVID-19 outbreak, primarily related to payroll, consulting support, IT infrastructure and facilities costs. Shares used to compute basic net income per share Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.Operating lease liabilities, net of current portionPreferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019Common stock, $0.001 par value, 200.0 million shares authorized; 96.2 million and 95.4 million shares issued and outstanding, respectively, at June 30, 2020; and 92.4 million and 91.6 million shares issued and outstanding, respectively, at December 31, 2019Treasury stock, at cost; 0.8 million shares at June 30, 2020 and December 31, 2019Shares used to compute basic net income (loss) per shareShares used to compute diluted net income (loss) per shareImpact of diluted shares on net income (basic net loss) per share The accompanying press release dated July 28, 2020 contains non-GAAP financial measures.
The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. Shares used to compute diluted net income per share
The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in Dexcom’s Quarterly Report on Form 10-Q for the period ended June 30, 2020, as filed with the Securities and Exchange Commission on July 28, 2020. "Our growth in the second quarter reflects the commitment of the Dexcom teams to rapidly adjust during the COVID-19 pandemic and ensure service to our customers and our communities," said Kevin Sayer, Dexcom’s chairman, president and CEO. The conference call will be concurrently webcast. This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future. The second quarter 2020 non-GAAP amount excludes $16.5 million of non-cash interest expense related to Dexcom’s senior convertible notes, $7.8 million of incremental costs incurred as a result of the COVID-19 outbreak and a $5.4 million loss on extinguishment of debt.